Correlation Between Molecular Partners and Unicycive Therapeutics
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Unicycive Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Unicycive Therapeutics.
Diversification Opportunities for Molecular Partners and Unicycive Therapeutics
0.3 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Molecular and Unicycive is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Unicycive Therapeutics go up and down completely randomly.
Pair Corralation between Molecular Partners and Unicycive Therapeutics
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.1 times more return on investment than Unicycive Therapeutics. However, Molecular Partners is 1.1 times more volatile than Unicycive Therapeutics. It trades about 0.08 of its potential returns per unit of risk. Unicycive Therapeutics is currently generating about 0.02 per unit of risk. If you would invest 389.00 in Molecular Partners AG on September 2, 2024 and sell it today you would earn a total of 193.00 from holding Molecular Partners AG or generate 49.61% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Partners AG vs. Unicycive Therapeutics
Performance |
| Timeline |
| Molecular Partners |
| Unicycive Therapeutics |
Molecular Partners and Unicycive Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and Unicycive Therapeutics
The main advantage of trading using opposite Molecular Partners and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.| Molecular Partners vs. Tff Pharmaceuticals | Molecular Partners vs. Eliem Therapeutics | Molecular Partners vs. Inhibrx | Molecular Partners vs. Enliven Therapeutics |
| Unicycive Therapeutics vs. Transcode Therapeutics | Unicycive Therapeutics vs. Cardio Diagnostics Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Complementary Tools
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |